Sun Pharmaceutical Industries, India's largest drugmaker by market capitalization, reported consolidated revenue of ₹15,299 crore for the June quarter, marking a 10.5% year-on-year increase. However, the company missed analyst expectations as net profit rose 27% to ₹2,895 crore, falling short of the Bloomberg poll estimates of ₹15,527 crore revenue and ₹2,974 crore net profit, according to livemint.com.
The revenue growth was driven by strong performance in Sun Pharma's domestic business and innovative medicines segment. Despite this, weakness in the US generics market weighed on overall profitability. The decline in US generics sales offset gains from other segments, preventing the company from meeting Street expectations. Shares of Sun Pharma closed 0.7% lower at ₹1,987 on the National Stock Exchange on Friday, reflecting investor reaction to the results.
This performance highlights ongoing challenges in the US generics sector, which has affected several Indian pharmaceutical companies. Sun Pharma's ability to sustain growth in its domestic and innovative medicines businesses partially mitigated the impact. The results underscore the importance of diversification in revenue streams for Indian drugmakers amid fluctuating international markets. The Bloomberg poll had anticipated stronger overall results, indicating cautious investor sentiment.
Sun Pharma's next quarterly earnings report is awaited to assess whether the company can improve its US generics performance and maintain momentum in domestic and innovative segments. The June quarter figures provide a benchmark for evaluating the company's strategic focus and market positioning in the evolving pharmaceutical landscape.